Effects of Mediterranean Diet on Subjective Cognitive Decline

Launched by CHIH-PING CHUNG · Feb 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of the Mediterranean diet on older adults who feel they are experiencing memory decline, a condition known as subjective cognitive decline (SCD). The researchers want to find out if this diet can help improve both physical and mental functions in these individuals. They will also look into how the Mediterranean diet may work on the brain and body, using brain scans and blood tests to understand the effects better.

To participate in this study, you need to be over 60 years old and have noticed a decline in your memory over the last five years, but your overall cognitive skills should still be good. The trial is open to anyone who meets these criteria, as long as they don't have certain health issues that could interfere with the diet. If you join, you will follow a Mediterranean diet for three months and take part in assessments to see how it impacts your health. This is an exciting opportunity to contribute to research that could help others facing similar challenges with memory.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Subjective cognitive decline (SCD)-plus subjects, individuals must meet five criteria:
• • 1. Subjective memory decline without impairment in other cognitive domains (MMSE \> 26; MMSE \> 14 for \<6 years of education).
• • 2. Onset of subjective cognitive decline within the past 5 years.
• • 3. Age at the onset of subjective cognitive decline is \>60 years.
• • 4. Concern and preoccupation with memory decline.
• • 5. Perceived functional decline relative to peers and meet one of three criteria: a. Caregiver perceives cognitive decline; b. Carries APOE ε4 genotype; c. Clinical evidence of preclinical Alzheimer's disease biomarkers.
• Exclusion Criteria:
• Exclude individuals who:
• • 1. Cannot comply with or accept the dietary intervention (e.g., dietary restrictions, vegetarianism, lactose intolerance).
• • 2. Have walking speed ≤ 0.3 meters/second.
• • 3. Have significant medical conditions affecting physical and cognitive functions.
• • 4. Have chronic kidney disease (eGFR \<30 ml/min/1.73m2) or undergo dialysis.
• • 5. Experience poorly controlled cardiovascular diseases or malignant tumors.
• • 6. Have severe visual and hearing impairments preventing assessments.
• • 7. Have undergone hormone therapy in the preceding three months or are expected to during the trial.